Global Cancer Therapy Related Diarrhea: 2020 Pipeline Insight Report – ResearchAndMarkets.com

Global Cancer Therapy Related Diarrhea: 2020 Pipeline Insight Report – ResearchAndMarkets.com




Global Cancer Therapy Related Diarrhea: 2020 Pipeline Insight Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cancer Therapy Related Diarrhea – Pipeline Insight, 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Cancer Therapy Related Diarrhea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Emerging Drugs Chapters

This segment of the Cancer Therapy Related Diarrhea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Emerging Drugs

Crofelemer: Napo Pharmaceuticals

Crofelemer is a drug that is a chloride channel antagonist and is presently being studied in Phase III of clinical trial. Originally, this compound was owned by Shaman Pharmaceuticals and currently under the development of Napo Pharmaceuticals.

Therapeutic Assessment

This segment of the report provides insights about the different Cancer Therapy Related Diarrhea drugs segregated based on following parameters that define the scope of the report, such as:

Major Players

There are approx. 2+ key companies which are developing the therapies for Cancer Therapy Related Diarrhea. The companies which have their Cancer Therapy Related Diarrhea drug candidates in the most advanced stage, i.e. phase III include, Napo Pharmaceuticals.

Phases

This report covers around 2+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Cancer Therapy Related Diarrhea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

  • Oral
  • Parenteral
  • intravitreal
  • Subretinal
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as:

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cancer Therapy Related Diarrhea therapeutic drugs key players involved in developing key drugs.

Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cancer Therapy Related Diarrhea drugs.

Key Topics Covered:

Introduction

Executive Summary

Cancer Therapy Related Diarrhea: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Cancer Therapy Related Diarrhea – Analytical Perspective

In-depth Commercial Assessment

  • Cancer Therapy Related Diarrhea companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Cancer Therapy Related Diarrhea Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Crofelemer: Napo Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Mid Stage Products (Phase II)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Early Stage Products (Phase I)

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Pre-clinical and Discovery Stage Products

  • Comparative Analysis

Drug Name: Company Name

  • Product Description
  • Research and Development
  • Product Development Activities

Inactive Products

  • Comparative Analysis

Cancer Therapy Related Diarrhea Key Companies

Cancer Therapy Related Diarrhea Key Products

Cancer Therapy Related Diarrhea- Unmet Needs

Cancer Therapy Related Diarrhea- Market Drivers and Barriers

Cancer Therapy Related Diarrhea- Future Perspectives and Conclusion

Cancer Therapy Related Diarrhea Analyst Views

Cancer Therapy Related Diarrhea Key Companies

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/x7k6rj

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900